鄭智聰醫生 - 臨床微生物及感染學
臨床微生物及感染學專科醫生
重點資料
- 醫務委員會註冊已驗證
- 臨床微生物及感染學專科醫生香港大學內外全科醫學士 · 英國皇家內科醫學院院士 · 香港病理學專科學院院士 · 1994 年醫科畢業
- 保險計劃資料整理中｜查看詳情
關於醫生
鄭智聰醫生是香港註冊的臨床微生物及感染學專科醫生。
學歷
臨床微生物及感染學專科醫生
- 香港大學內外全科醫學士1994
- 英國皇家內科醫學院院士1997
保險計劃
常見問題
鄭智聰醫生好嗎？
鄭智聰醫生是香港註冊的臨床微生物及感染學專科醫生。資歷及註冊資料來自香港醫務委員會。ok.med 不評分，也不排名。
鄭智聰醫生是做什麼的？
鄭智聰醫生是臨床微生物及感染學醫生。
研究及論文
共 207 篇，顯示最近 12 篇
按論文主題篩選
主題由同一批 PubMed 論文的醫學分類整理，不代表醫生提供相關診治服務。
- 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
- 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
- 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
- 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
- Universal decolonization for methicillin-resistant <i>Staphylococcus aureus</i> and carbapenem-resistant <i>Acinetobacter</i> in elderly homes: A large cohort of over 16,000 residents in Hong Kong.Public health in practice (Oxford, England) · 2026
- Epidemiology and clinical characteristics of rat hepatitis E virus infection in humans.The Journal of infection · 2026
- 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
- 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
- Bridging borders: adapting the Orange County methicillin-resistant <i>Staphylococcus aureus</i> decolonization protocol for an infirmary unit in Hong Kong.Infection control and hospital epidemiology · 2026
- 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
- Can machine learning support infection control measures by predicting carbapenemase-producing Enterobacterales colonization at admission?Infection control and hospital epidemiology · 2026
- Tracking SARS-CoV-2 RNA in the air: Lessons from a COVID-19 outbreak in an infirmary unit.American journal of infection control · 2025
論文資料來自 PubMed／Europe PMC，按姓名及機構自動配對；每項均可按連結核對。
僅供參考，不構成醫療建議。 閱讀完整免責聲明